Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

World-First Approval For Novel Anthrax Vaccine

 
• By Jung Won Shin
  
first quarter results
SK Biopharm, Yuhan Benefited From Global Sales Of Flagship New Drugs (Shutterstock)

More from Earnings

More from South Korea